Medtronic PLC $MDT Stock Holdings Lifted by Sagespring Wealth Partners LLC

Sagespring Wealth Partners LLC lifted its stake in shares of Medtronic PLC (NYSE:MDT) by 20.5% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 29,386 shares of the medical technology company’s stock after acquiring an additional 5,008 shares during the quarter. Sagespring Wealth Partners LLC’s holdings in Medtronic were worth $2,799,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of MDT. AXQ Capital LP grew its position in Medtronic by 25.6% during the 2nd quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock worth $862,000 after purchasing an additional 2,013 shares in the last quarter. GC Wealth Management RIA LLC lifted its holdings in shares of Medtronic by 20.6% in the second quarter. GC Wealth Management RIA LLC now owns 33,569 shares of the medical technology company’s stock valued at $2,926,000 after purchasing an additional 5,734 shares in the last quarter. Merit Financial Group LLC boosted its position in shares of Medtronic by 37.5% in the second quarter. Merit Financial Group LLC now owns 57,035 shares of the medical technology company’s stock worth $4,972,000 after buying an additional 15,561 shares during the period. Verdence Capital Advisors LLC grew its holdings in shares of Medtronic by 22.0% during the second quarter. Verdence Capital Advisors LLC now owns 29,396 shares of the medical technology company’s stock valued at $2,562,000 after buying an additional 5,296 shares in the last quarter. Finally, World Investment Advisors raised its position in Medtronic by 1.9% during the second quarter. World Investment Advisors now owns 156,107 shares of the medical technology company’s stock valued at $13,608,000 after buying an additional 2,868 shares during the period. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MDT has been the subject of a number of research reports. Morgan Stanley raised their price objective on Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 19th. Truist Financial cut their price objective on Medtronic from $110.00 to $107.00 and set a “hold” rating for the company in a report on Thursday, December 18th. Sanford C. Bernstein upped their target price on Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a research report on Friday, January 9th. TD Cowen reaffirmed a “buy” rating on shares of Medtronic in a research report on Friday, November 14th. Finally, Royal Bank Of Canada increased their price target on shares of Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. Fourteen research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.28.

Medtronic Stock Down 0.4%

NYSE MDT opened at $100.98 on Monday. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The stock has a market cap of $129.45 billion, a PE ratio of 27.22, a PEG ratio of 2.66 and a beta of 0.71. The firm has a 50-day simple moving average of $99.44 and a 200 day simple moving average of $95.32. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter in the prior year, the firm posted $1.26 EPS. The company’s revenue for the quarter was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were paid a dividend of $0.71 per share. The ex-dividend date was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.8%. Medtronic’s payout ratio is currently 76.55%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).